Bajaj Finserv Healthcare Fund
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Growthvine rating: 1/5 — ranked #75 of 84 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹11.71 (as of 2026-08-21) |
|---|
| AUM | ₹377 Cr |
|---|
| Expense ratio | 2.09% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Siddharth Chaudhary |
|---|
| Exit load | 1% for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -15.91% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 96.0% of NIFTY Pharma's upside and 97.9% of its downside.
Market cap allocation
| Large cap | 31.6% |
|---|
| Mid cap | 25.9% |
|---|
| Small cap | 42.5% |
|---|
Concentration
| Top 5 holdings | 37.8% |
|---|
| Top 10 holdings | 61.9% |
|---|
| Total holdings | 32 |
|---|
Top holdings
- Divis Laboratories Ltd. — 9.7%
- Sun Pharmaceutical Industries Ltd. — 8.9%
- PIRAMAL PHARMA LIMITED — 6.6%
- Apollo Hospitals Enterprises Ltd. — 6.5%
- Aurobindo Pharma Ltd. — 6.1%
- RUBICON RESEARCH LIMITED — 6.0%
- Torrent Pharmaceuticals Ltd. — 5.5%
- Neuland Laboratories Limited. — 4.4%
- Emcure Pharmaceuticals Limited — 4.4%
- Max Healthcare Institute Limited — 3.8%
Top sectors
- Pharma & Biotech — 69.2%
- Healthcare — 18.4%
- Food Beverage & Tobacco — 2.7%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 21.6% | Q1 (Top) | #6 of 76 |
| 2025 | -4.6% | Q4 (Bottom) | #55 of 69 |